In COVID-19 clinical update #115, Dr. Griffin reviews cross-variant immunity without vaccination, EUA for boosters in 5-11 year olds, B.1.1.529 attack rate, scent dogs, Omicron and pets, Paxlovid, Veklury, Fluvoxamine, antigen positivity after isolation, inflammasome activation and severe disease, and GI persistence and fecal shedding.
TWiV celebrates 900 episodes, Vincent gives the Richard R. Ernst lecture, and we discuss why inflammasome activation in infected macrophages drives severe COVID-19. Hosts: Vincent Racaniello, Alan Dove, Rich Condit, Kathy Spindler, and Brianne Barker Click arrow to playDownload TWiV 900 (65 MB .mp3, 108 min)Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Show notes at microbe.tv/twiv
TWiV explains a study of how climate change is predicted to increase cross-species viral transmission risk, and increased memory B cell potency and breadth after a SARS-CoV-2 mRNA vaccine boost. Hosts: Vincent Racaniello, Dickson Despommier, and Amy Rosenfeld Click arrow to playDownload TWiV 896 (65 MB .mp3, 108 min)Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Show notes at …
In COVID-19 clinical update #112, Dr. Griffin reviews seroprevalence of infection-induced antibodies, Moderna filing for vaccine authorization in young children, public health impact of vaccines in US, FDA approval of first treatment for young children, phase 2 data for Sabizabulin, and post infection inflammation.
TWiV explains what is known about cases of acute, severe hepatitis of unknown origin in children, and discovery of an inhibitor of TMPRSS2 protease that blocks SARS-CoV-2 infection.
This episode of TWiV is focused on COVID-19 vaccines and antibodies: who should get boosters, whether a variant matched mRNA vaccine is superior to a historical vaccine, and how the interval between vaccination and infection influences the quality of the antibody response.
